Lurbinectedin's Primary Mechanism
Lurbinectedin (trade name Zepzelca) binds to DNA minor grooves in tumor cells, blocking transcription and causing double-strand DNA breaks. This triggers apoptosis primarily in rapidly dividing cancer cells, such as those in small cell lung cancer (SCLC). It inhibits RNA polymerase II, leading to accumulation of DNA damage and cell death without directly targeting immune checkpoints like PD-1/PD-L1 inhibitors.[1]
Direct Effects on Immune Response
Lurbinectedin induces immunogenic cell death (ICD), where dying tumor cells release damage-associated molecular patterns (DAMPs) like HMGB1 and calreticulin. These signals attract dendritic cells and promote antigen presentation to T cells, enhancing anti-tumor immune activation. In preclinical models, it increases tumor infiltration by CD8+ T cells and natural killer (NK) cells, boosting cytotoxic responses against cancer cells.[2][3]
Synergy with Immunotherapy
Lurbinectedin upregulates MHC class I on tumor cells and PD-L1 expression, making tumors more visible to the immune system. Combined with PD-1 inhibitors like atezolizumab or pembrolizumab, it shows additive effects: chemotherapy clears bulk tumor while immunotherapy sustains T-cell attack. Phase II trials in SCLC reported improved progression-free survival (e.g., 5.8 months vs. 4.1 months with immunotherapy alone).[4]
Impact on Immune Cells and Microenvironment
It depletes myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) in the tumor microenvironment, reducing immunosuppression. Mouse studies demonstrate reduced TGF-β secretion, which otherwise hinders T-cell function. However, high doses can cause transient lymphopenia, potentially delaying immune recovery short-term.[5]
Clinical Evidence in Trials
In the IMforte trial (NCT03337698), lurbinectedin plus atezolizumab yielded 37% objective response rate in relapsed SCLC, with immune biomarkers (e.g., higher TILs) correlating to better outcomes. Real-world data show it reshapes the tumor immune landscape, increasing neoantigen-specific T cells.[6]
Limitations and Patient Considerations
Effects vary by tumor type and mutational burden; less immunogenic in low-TMB cancers. Neutropenia (60% incidence) may indirectly impair immune function during treatment cycles. No head-to-head trials vs. other chemo-immuno combos exist yet.[1][4]
Sources
[1]: FDA Label for Zepzelca
[2]: Trigo et al., Lancet Oncol (2020)
[3]: Paz-Ares et al., Lancet Oncol (2019)
[4]: ClinicalTrials.gov (NCT03337698)
[5]: Int Rev Immunol (2021)
[6]: ESMO Congress abstracts (2022)